5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests.
INTRODUCTION
The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug capecitabine, are the cornerstone of treatment of numerous types of cancer. The use of fluoropyrimidines is associated with numerous side effects, such as myelosuppression, hand-foot syndrome, mucositis, diarrhea and occasionally cardiac toxicity.
After parenteral administration of 5-FU, 70-90% of the parent drug is degraded by dihydropyrimidine dehydrogenase (DPD). [1] [2] [3] [4] [5] A small proportion of patients develop extreme toxicity after administration of a fluoropyrimidine due to a partial or complete DPD deficiency and hence a strongly reduced capacity to degrade 5-FU. [6] [7] [8] [9] [10] In case of complete DPD deficiency, 5FU treatment may even result in a lethal outcome. 11 It was initially estimated that in 3-5% of Caucasians the activity of DPD is strongly reduced due to (epi)genetic variations in the gene encoding DPD. 4, 12 However, this percentage has been disputed as there is still no consensus on the definition of DPD deficiency, and therefore the incidence of DPD deficiency reported in numerous studies is strongly dependent on the method used to assess DPD deficiency 13 and the cutoff level chosen to define DPD deficiency. 5 Prospective testing for DPD deficiency in patients might prevent DPD-deficient patients from severe toxicity or even death. In this review, we describe current methods for determination of DPD deficiency. We discuss the potential and limitations of these tests for routine clinical use. In addition, we have defined recommendations that can help successful implementation of a pre-emptive testing strategy to predict fluoropyrimidine-related toxicity.
METHODS
To identify studies describing diagnostic tests to detect DPD deficiency, a systematic MEDLINE, EMBASE, Web of Science and Cochrane search was conducted using the following combination of MESH terms:, 'dihydropyrimidine dehydrogenase deficiency', 'dpd deficiency', 'Familial Pyrimidinemia', 'uracil', 'capecitabine', 'dihydrouracil dehydrogenase (nadp)', 'dihydrouracil dehydrogenase', 'dihydropyrimidine dehydrogenase', 'dihydrouracil dehydrogenase (nad þ )' and 'dpd'. The search resulted in 397, 378, 568 and 28 hits for MEDLINE, EMBASE, Web of Science and Cochrane, respectively. The unique hits collected from these databases were selected and further limited to English language papers from 1980 to 1 January 2012. Papers describing studies aimed at testing DPD activity and/or DPD deficiency in volunteers or patients were selected. Cross references were identified from bibliographies from the selected studies. Only articles that describe the complete performance of the test were included; reviews and papers describing in vitro studies including DPD activity in cancer cells or studies in animals were neglected. The collected publications were divided into three categories, describing tests aimed at assessing DPD enzyme activity (38 articles), genetic variants in DPYD (20 articles) and mRNA variants (3 articles).
Tests aimed at assessing (surrogates for) DPD enzyme activity Several tests have been described to assess the activity of the enzyme DPD.
DPD activity in peripheral blood mononuclear cells (PBMCs). The majority of DPD is reported to be in the liver, 1, 14 but DPD activity in other tissues such as lymphocytes contribute to metabolism of fluoropyrimidines as well. 15 The liver DPD activity in patients revealed a strong correlation with DPD activity in PBMCs. 16 The mean DPD activity in PBMCs of patients with a partial DPD deficiency is approximately 48% to that observed in the normal population due to heterozygosity for a pathological mutation. 17 The methodology of the test includes incubating isolated lymphocytes with radioactive labeled 5-FU or thymine after which the degradation products are measured by high-performance liquid chromatography (HPLC) with a radioisotope flow detector.
2,18-20 A HPLC-electrospray tandem mass spectrometry (HPLC MS/MS) method has also been developed. 17, 21 The use of a porous graphitic carbon column 22 results in a HPLC process that is highly pH stable compared with the reversed-phase C-18 column, and the detection limit was at least similar to the C-18 columns with considerably shorter analysis time. This method was validated ( Table 1) . Evaluation of the stability of DPD in PBMCs indicated that the DPD activity decreased approximately 50% upon freezing but was 
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Predictive tests for DPD MC van Staveren et al stable for at least 1 month. 16 The stability of radioactive 5-FU and its metabolite dihydrofluorouracil (DHFU) in the reaction mixture was found to be stable for 3 months and not affected by at least three freeze-thawing cycles. 19 The use of an on-line radioisotope flow detector makes this method very useful as a semi-automated radioassay, but the implementation on a broad scale might be hampered by the specific equipment that is necessary. The correlation between DPD activity in PBMCs and systemic 5-FU clearance has been studied, but the results are contradictive. One study found a good correlation, 2 but two other studies found a much poorer relation. 4, 23 Instead of radiolabeled substrates, the use of non-radiolabeled thymine as substrate was investigated. 17 Nevertheless, because of the superior sensitivity of radiochemical assays, the presence of a complete DPD deficiency can be established only with the DPD assay that use radiolabeled substrates. 18, 19, 22 The distinction between a partial and complete DPD deficiency is important to make, because in the case of a partial deficiency the oncologist might consider dose reduction. Complete DPD deficiency may lead to switching to a nonfluoropyrimidine-containing regimen. In general, the assays to measure DPD activity in PBMCs are labor intensive and therefore expensive. For this reason, it is not likely that this method is suitable to use broadly in clinical practice.
Uracil breath test. The principle of this test is that after ingestion of an aqueous solution of 2- C-uracil by DPD followed by the other two enzymes of the pyrimidine degradation pathway takes place resulting in the production of 13 CO 2 , [24] [25] [26] which is determined in exhaled breath using IR spectroscopy (UBiT-IR 300 ). In DPDdeficient individuals, reduced 2-13 C-uracil catabolism results in decreased exhaled 13 CO 2 levels. The amount of 13 CO 2 present in breath samples is expressed as delta over baseline ratio that represents a change in the 13 CO 2 / 12 CO 2 ratio of breath samples collected before and after 2-13 C-uracil ingestion. The breath test was evaluated in multiple studies with volunteers and cancer patients with or without (partial) DPD deficiency and has been extensively validated (Table 1) . One study compared the plasma 2-13 C-uracil pharmacokinetics with expired 13 CO 2 in subjects with normal and reduced PBMC DPD activity. 25 The results of this study showed that Tmax and Cmax in exhaled air are not correlated to plasma Cmax and Tmax. The breath test is rapid and non-invasive as it only requires exhaled air from patients which is collected into sealed bags that are transported to a central laboratory. The integrity of the breath collection bags was stable for up to 201 days after their initial examination. However, the transportation may delay the availability of outcome of the test result for the physician, possibly delaying the start of chemotherapy. A broad clinical use of this test is further hampered by the limited availability of the expensive 2-13 C-uracil and the fact that the UBiT-IR 300 spectrophotometer that is needed for the analysis is not commonly available in every hospital and must be purchased specially for this test.
Uracil oral loading dose. The uracil loading dose uses uracil as a marker to determine possible DPD deficiency. 27 This test is currently under investigation in two clinical trials. Uracil is administered orally to individuals after which blood samples are withdrawn at predetermined time points. The amount of uracil and its metabolite dihydrouracil (DHU) are measured in plasma. The doses of uracil that were tested were 500 and 1000 mgm À 2 , but the higher dose had no substantial benefits compared with the lower dose. In the group that received 500 mgm À 2 , the pharmacokinetic parameters of U and DHU in subjects with DPD deficiency differed significantly compared with subjects with normal DPD activity. An advantage of this test is that uracil is relatively inexpensive compared with the 2-13 C-uracil that is used for the breath test. Uracil is only available as a pharmaceutical ingredient and not as a licensed drug substance, necessitating a drug formulation step before use. Uracil in plasma can be measured with HPLC, which makes it suitable for broad clinical implementation. The sampling scheme that is currently used is extensive and for that reason less convenient for the patient. In addition, the sensitivity and specificity of this test have not yet been determined that makes it impossible to compare with other methods.
Endogenous U/DHU or DHU/U ratio. Besides the ex vivo measurement of DPD activity in human cells, alternative assays have been developed, including the analysis of endogenous uracil (U) and/or DHU levels or their ratio in plasma [28] [29] [30] [31] [32] [33] [34] or urine. 20, 35 In case of a (partial) DPD deficiency, the breakdown of U is impaired causing elevated endogenous uracil levels and decreased DHU levels in biological fluids, such as plasma or urine. U and DHU can be measured by HPLC 36 and GC 29 methods, which have been validated (Table 1) . A strong correlation was detected between the DHU/U ratio in plasma with 5-FU half-life, clearance and plasma levels. 30, 32, 33 However, it was reported that in some individuals with a normal U/DHU ratio strongly elevated 5-FU levels were measured, indicating that determination of the U/DHU ratio may not always correctly reflect 5-FU levels. 37 The stability of uracil in plasma is at least 2 months at À 80 o C.
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A significant circadian rhythm in plasma and urine DHU/U ratio and DPD activity in mononuclear cells was observed in healthy subjects, but this was disrupted in patients who were continuously infused with a high dose of 5-FU. 38 The biological significance of the DPD circadian pattern to fluoropyrimidine drug treatment is obvious, as the variations in DPD between individuals can result in 5-FU concentration fluctuations, which can be directly correlated with treatment toxicity. The circadian rhythm in a population of patients and volunteers should be investigated to determine threshold values for those patients who are prone to toxicity. The good stability of uracil in plasma and the fact that the HPLC equipment needed for this assay is available in most clinical laboratories make this method suitable for broad clinical implementation.
5-FU therapeutic drug monitoring. The pharmacokinetics of 5-FU and its metabolite DHFU can be assessed to detect possible DPD deficiency. The determination of plasma concentrations of 5-FU and DHFU can be performed by HPLC, 31, 39, 40 LC-MS/MS 41 or immunoassay. 42 These methods have been validated (Table 1) 31,39,42 Based on this principle, several investigators hypothesized that the administration of a test dose of 5-FU before the start of chemotherapy might enable identifying subjects at risk of severe treatment-related side effects. 8, 39, 40, [43] [44] [45] [46] The test doses 5-FU investigated were 250, 300, 370 and 450 mgm À 2 after which 5-FU and DHFU were measured in plasma. The pharmacokinetic results following a test dose of 250 mgm À 2 5-FU were significantly different from a dose of 370 mgm À 2 , 44 but there was no linear correlation between 5-FU and DHFU pharmacokinetics and no correlation between DPD activity and 5-FU pharmacokinetics following a dose of 250 mgm À 2 . In one study, test doses of 300 or 450 mgm À 2 were used in subjects with and without the presence of the c.1905 þ 1G4A mutation. 46 Only with the dose of 450 mgm À 2 , the mean area under the curve and clearance of 5-FU was significantly different, but the terminal half-life of 5-FU measured at both test doses showed a highly significant difference. A limited sampling model based on two time points was studied in patients receiving 370 mgm À 2 5-FU as an intravenous bolus making the test more suitable for clinical practice and less patient intensive. 45 More recently, a validated limited sampling PK model was presented based on a single sample after 300 or 450 mgm À 2 5-FU. Normal and DPD-deficient patients could be discriminated at 300 mgm À 2 . 8 Because of the simple methodology and analysis, this test can be easily performed in hospital settings. A potential disadvantage of this method is that the test dose of 5-FU might cause toxicity in severely deficient DPD patients (that is, homozygous DPD deficient). One study showed no toxicity in 20 of 22 patients heterozygous for the c.1905 þ 1G4A after the administration of the single doses of 5-FU 300 and 450 mgm À 2 . 8 However, possible toxic reactions following a 5-FU test dose in severely deficient patients should be studied further in a larger population.
Tests aimed at assessing genetic variants in DPYD, the gene encoding DPD Denaturing HPLC (DHPLC). One possible method to detect DNA mutations involves DHPLC. [47] [48] [49] This assay is based on temperature-dependent separation of DNA containing mismatched base pairs from a pool of PCRamplified DNA fragments. This method is highly sensitive and can detect heterozygous variants. Homozygous wild-type vs homozygous mutated sequences are not really resolved by this method. To detect homozygous mutations, mixing of each sample with a wild type sample is necessary. For sequencing samples with aberrant peak patterns, it is necessary to finally determine the kind of mutation with the use of a secondary test, which will increase the total cost. DHPLC can be used to detect currently unrecognized unknown sequence variations in the DPYD gene. The DNA is isolated out of the blood obtained by a single venapuncture. It takes approximately 250 min to screen the DPYD gene for mutations at one temperature. 47 A drawback of the DHPLC method is that it is laborious and time consuming, and for that reason, not suitable for large numbers of patients. Secondly, the equipment that is used is not available in every hospital laboratory. With this technique, the 23 DPYD exons were screened in DNA samples of randomly selected individuals, DPD-deficient patients and patients who experienced toxicity following 5-FU treatment. [47] [48] [49] Missense mutations in the DPYD gene will not necessary lead to reduced DPD activity. Gross et al. 49 analyzed DNA of four individuals with symptoms of 5-FU-related toxicity and compared the data with control samples of 157 healthy individuals. Several missense mutations were found in the DNA of the patients, but only in one patient with four mutations a lower DPD activity in PBMCs was found. This result displays a general problem that can be found with genotyping and 5-FU-related toxicity. For a good predictive value, there has to be a clear correlation between genetic variants and its effect on DPD activity or the likelihood to develop toxicity. A solution to encounter this problem is to determine the impact of novel mutations found in the DPD gene on enzyme activity. [49] [50] [51] Pyrosequencing. Pyrosequencing [51] [52] [53] [54] [55] [56] [57] is based on the utilization of ATP to produce light. The pyrosequencing reaction results in the release of a pyrophosphate molecule with the sequential incorporation of bases to the DNA template. The technique is developed into a fully automated process as a result of advanced equipment that allows genotyping of multiple samples within an hour. However, the initial investment in the equipment is around Euro 50 000-80 000, and as a result, it is not available in every hospital laboratory. The technique of pyrosequencing and its role in detecting mutations in the DPYD gene has been extensively studied in volunteers and cancer patients. In a population of 14 individuals with a reduced DPD activity and severe 5-FU-related toxicity, 57% had a molecular basis for their deficient phenotype. 57 Three DPYD variants, the c.1905 þ 1G4A, c.2846A4T and c.1236G4A, were strongly associated with fluoropyrimidine-induced toxicity. [58] [59] [60] In a large population of 487 patients, one-third of the patients with one of the single-nucleotide polymorphisms (SNPs) had no adverse reactions, and therefore the presence of a SNP will not automatically imply the development of toxicity following 5-FU therapy. Interestingly, the absence of a SNP will also not exclude developing toxicity as in several studies patients were identified who had no SNP but still suffered from severe initial side effects as a result of a lowered 5-FU plasma clearance. 53, 54, 61 The determination of a single SNP can be easily performed in hospital settings and costs, at this moment, around 25 Euros per SNP. Determination of multiple clinically relevant SNPs could potentially enhance sensitivity and specificity. Pyrosequencing is used more and more in daily practice before 5-FU administration despite the lack of prospective evidence of its usefulness. Like all PCR-based tests, a disadvantage of pyrosequencing is that with this method only SNPs and small deletions are detected. Large genomic deletions are missed and especially those that are present in the DPD gene.
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Restriction fragment-length polymorphism (RFLP). RFLP is a technique in which DNA is spliced into fragments by restriction enzymes. Following the splicing, the DNA fragments are separated by gel electrophoresis. RFLP has been used in studies that investigated the presence of the c.1905 þ 1G4A mutation in cancer patients with 5-FU-related toxicity.
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Single-strand conformation polymorphisms (SSCP). SSCP is a technique that was also optimized to be useful for pharmacogenetic DPD studies and can be used to detect DNA sequence changes. The principle of SSCP is based on changes in the secondary structures in single-strand DNA fragments caused by a change in sequence, which are detected as alterations in fragment mobility by gel electrophoresis. The conditions of SSCP were optimized with an automated system to screen genetic polymorphisms in the DPYD gene and its efficacy was evaluated by using 21 DNA samples with previously characterized polymorphisms. 63 The polymorphism detection rate of this technique was 95.3%.
Epigenetics. Since the observation in several studies that DPYD sequence variants could not fully explain the molecular basis of DPD deficiency, it is hypothesized 64, 65 that methylation of the DPYD promoter might be an alternative mechanism for DPD deficiency in cancer patients. Methylation of CpG islands located in the 5 0 -regulatory region of the DPYD gene has been shown to inhibit transcription. 64 The methylation status of DNA fragments can be detected with the use of DHPLC or with pyrosequencing. One study showed a significant association between aberrant methylation of the DPYD promoter and DPD enzyme deficiency in 80% of DPD-deficient individuals, whereas all individuals with normal DPD enzyme activity tested negative for methylation. 64 In contrast, other studies did not confirm the role of DPYD promoter hypermethylation to the development of severe 5-FU toxicity. 66, 67 The contradictory results of the studies investigating the role of methylation of the DPYD promoter make it unlikely that screening for aberrant methylation of the promoter of DPYD will become current practice soon.
Tests aimed at assessing mRNA variants encoding DPD DNA mutations can result in altered mRNA levels or aberrant splicing of the pre-mRNA. It is hypothesized that DPD enzyme activity is possibly correlated with DPD mRNA expression. 68 Using a reverse transcription-PCR-based assay, the exon 14 skipping mutation has been studied in patients with and without grade 3-4 toxicity following 5-FU therapy. 69 The DPD enzyme activity correlated with DPD mRNA expression in biopsy-sized tissue samples, including PBMCs. 70 A disadvantage of mRNA screening is the instability of mRNA in the blood that makes it unsuitable for routinely screening, as the equipment needed for mRNA screening is not widely available in every hospital. For this reason, it is unlikely that this technique is suitable for prospective screening of large number of patients.
DISCUSSION

Predicting toxicity
The aim of the tests described in this review is to predict and prevent extreme toxicity following 5-FU treatment by detecting DPD deficiency, which results in decreased 5-FU clearance leading to a higher incidence of side effects. However, some patients who suffer from severe side effects caused by 5-FU show normal 5-FU pharmacokinetics or wild-type DPYD genotype, and therefore it is important to realize that prospective testing for DPD deficiency will not exclude all 5-FU-related toxicity.
Sensitivity and specificity Tests at the DNA and RNA level can be used to determine the presence of certain mutations in the DPYD gene. Analysis of the prevalence of the various mutations in the DPD gene (DPYD) revealed that three mutations, c.1905 þ 1G4A, c.2846A4T and c.1129-5923C4G, were most frequently associated with toxicity. 5, 11, 54, [58] [59] [60] 71 Unfortunately, fluoropyrimidine toxicity is only partly explained by mutations in the coding region of DPYD. 59 With respect to overall toxicity, the sensitivity for screening for only the c.1905 þ 1G4A mutation was 5.5% 72 and 31% for c.1905 þ 1G4A, c.2846A4T (p.D949V) and c.1679T4G. 54 Until now, only coding areas and flanking intron sequences have been analyzed, though deep intron mutations might influence the splicing of DYPD pre-mRNA, as was demonstrated recently. 59 In the case of a test to detect DPD deficiency, a high sensitivity is essential as low specificity might lead to unnecessary dose reduction and therefore suboptimal therapy. A solution for this might be to develop a 5-FU dose escalation model, 73 but this has to be studied more intensively for different types of cancer and 5-FU treatment.
Definition of DPD deficiency Among the tests described, there is wide variation in the definition of DPD deficiency. The lack of a clear definition of DPD deficiency might hamper the implementation of prospective screening on a broad scale. With phenotyping, a patient is considered to be DPD deficient if the DPD activity is below a subjective pre-set threshold value. DPD activity measured in PBMCs has the problem that its precision largely depends on the isolated PBMC sub-fractions of blood cell components, which can be variable. 74 With genotyping studies, DPD deficiency is often defined as the presence of one or multiple SNPs, but the correlation between the genotype and diminished 5-FU clearance of all known polymorphisms has not been clarified.
Cost effectiveness
The cost-effectiveness aspects of methods that can be used for prospective DPD screening are sparsely described. The prevalence of partial DPD deficiency in Caucasian population is at least 3%. 4, 12, 54 As a result, many patients need to be screened pre-emptively in order to diagnose those with DPD deficiency.
Generally, genotyping is more simple and less patient invasive than phenotyping tests. However, the main problem with genotyping is the relatively low sensitivity and specificity. The determination of multiple SNPs with high prevalence might help to enhance sensitivity. Phenotyping tests for now seem to have a better correlation with the occurrence of 5-FU toxicity, but as with the genotyping strategy, sensitivity and specificity have to be established and improved.
In order to improve broad clinical implication of a diagnostic DPD test, we make the following considerations:
To enhance sensitivity of preventing fluoropyrimidine toxicity, future studies should investigate the optimization of the genotyping and fenotyping strategy to determine which test principle is in favor for detection of DPD-deficient patients. When the effectiveness of a test is established, future studies regarding this test should specifically focus on the costeffectiveness. A consensus definition of DPD deficiency has to be derived internationally to establish incidence of DPD deficiency and to compare study results. Sensitivity and specificity regarding prevention of fluoropyrimidine-related toxicity of every test have to be determined.
In conclusion, several tests are available to screen patients for DPD deficiency before their first treatment with fluoropyrimidines in a rapid and possibly low invasive way. At this moment, the challenge is to optimize the tests and to determine which test strategy is most suitable to predict patients at risk of developing fluoropyrimidine-related toxicity caused by DPD deficiency and to incorporate pre-emptive screening broadly into daily routine.
